BiotechTube
Anwita Biosciences

Anwita Biosciences

San Carlos, United States· Est.
anwitabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35M

Overview

Anwita Biosciences is a private, clinical-stage biotech leveraging an integrated technology platform for protein engineering to develop novel immunotherapies and targeted oncology treatments. Its lead asset, AWT020 (an anti-PD-1-IL-2 fusion protein), is in Phase 1 trials and has received FDA Orphan Drug Designation for thymic epithelial tumors. The company's strategy combines a deep biological understanding with rational engineering for selectivity and safety, supported by strategic partnerships and venture financing to advance its pipeline.

OncologyAutoimmune Diseases

Technology Platform

Integrated platform combining antibody discovery, cytokine engineering, proprietary ADC toxin-linker tech, and AI-assisted protein design to tune affinity, receptor bias, safety, and developability.

Funding History

3
Total raised:$35M
Series A$25M
Seed$5M
Seed$5M

Opportunities

AWT020's Orphan Drug Designation and novel mechanism provide a potential fast-track path in a niche indication while targeting large solid tumor markets.
The cancer cachexia program (AWT038) addresses a major unmet need with no approved therapies, representing a blockbuster opportunity.
The integrated platform enables rapid generation of diverse candidates, attracting potential partnership deals across multiple modalities.

Risk Factors

High clinical risk as novel mechanisms like AWT020 may fail in human trials.
Intense competition in immuno-oncology from large pharma with greater resources.
Significant financing risk as a private company needing capital to advance a broad pipeline through costly clinical development.

Competitive Landscape

AWT020 competes in the crowded PD-1 combination space, facing off against large pharma combos and other engineered cytokine approaches (e.g., NKTR-214, bempegaldesleukin). Its ADC and T-cell engager programs enter competitive fields dominated by companies like AstraZeneca, Genmab, and Amgen. Differentiation relies on novel mechanisms, receptor bias, and improved safety profiles.

More companies in Biologics / Biosimilars →More companies in United States →